Armistice Capital appears in the 13F filings of multiple specialty pharmaceutical companies, reflecting a portfolio strategy concentrated on drug developers with active regulatory pipelines across rare diseases, neurological conditions, and cardiovascular medicine. The fund manages more than $7 billion in assets and ranks among the more active healthcare-focused hedge funds tracked in institutional holdings databases. 13F filings are required of institutional investment managers holding more than $100 million in equity assets and offer a quarterly window into the positioning of major holders across publicly traded companies.
Funds with similar healthcare orientations, including Baker Bros. Advisors, RTW Investments, Wellington Management, and Driehaus Capital Management, frequently appear alongside Armistice in the shareholder registers of small- and mid-cap biopharma companies. Their collective presence in the same stocks can reflect a convergence of independent analysis among active managers who have each evaluated a company’s pipeline or regulatory outlook and reached similar conclusions about near-term valuation drivers.
Armistice’s disclosed equity positions include stakes in PTC Therapeutics, Supernus Pharmaceuticals, Travere Therapeutics, and Cytokinetics. PTC, which focuses on rare-disease drug development, shows Armistice holding approximately 5.43 million shares, or about 6.86% of shares outstanding. Supernus Pharmaceuticals, a neurology-focused company with marketed treatments for seizure disorders and an active development pipeline, accounts for approximately 5.2 million shares and roughly 2.55% of Armistice’s disclosed portfolio. Each of these holdings also attracts significant passive ownership from Vanguard Group and BlackRock, whose presence reflects broad index-based mandates rather than active thesis-driven positioning.
The aggregate institutional ownership profiles of the companies in Armistice’s portfolio suggest that the fund is participating in a broader institutional interest in specialty pharmaceutical stocks, particularly those with identifiable near-term catalysts. Tracking 13F filings from funds including Armistice Capital gives market observers one data point among many in a broader institutional picture that spans passive index holders, large active managers, and concentrated specialist funds with deep sector focus.